dasselta
krka, d.d., novo mesto - desloratadin - rhinitis, allergic, perennial; rhinitis, allergic, seasonal; urticaria - antihistaminer til systemisk brug, - dasselta er indiceret til lindring af symptomer forbundet med allergisk rhinitis;urticaria.
alk 761 hasselnød 1:20 w/v opløsning til priktest (soluprick)
alk-abello a/s - hasselnød - opløsning til priktest (soluprick) - 1:20 w/v
alk (113) corylus avellana 10 hep opløsning til priktest (soluprick-sq)
alk-abello a/s - hassel - opløsning til priktest (soluprick-sq) - 10 hep
alk (113) corylus avellana 100.000 sq-e/ml injektionsvæske, suspension
alk-abello a/s - hassel - injektionsvæske, suspension - 100.000 sq-e/ml
alk (113) corylus avellana behandlingssæt injektionsvæske, suspension
alk-abello a/s - hassel - injektionsvæske, suspension - behandlingssÆt
duodopa 20+5 mg/ml enteralgel
abbvie a/s - carbidopa, levodopa - enteralgel - 20+5 mg/ml
itulazax 12 sq-bet frysetørret sublingual tablet
alk-abello a/s - betula verrucosa ehrh. (vortebirk, synonym af b. pendula roth) - frysetørret sublingual tablet - 12 sq-bet
itulazax 12 sq-bet fryset?rret sublingual tablet
2care4 aps - betula verrucosa ehrh. (vortebirk, synonym af b. pendula roth) - frysetørret sublingual tablet - 12 sq-bet
carvykti
janssen-cilag international nv - ciltacabtagene autoleucel - multipelt myelom - carvykti is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti-cd38 antibody and have demonstrated disease progression on the last therapy.
yescarta
kite pharma eu b.v. - axicabtagene ciloleucel - lymphoma, follicular; lymphoma, large b-cell, diffuse - antineoplastiske midler - yescarta is indicated for the treatment of adult patients with diffuse large b cell lymphoma (dlbcl) and high-grade b-cell lymphoma (hgbl) that relapses within 12 months from completion of, or is refractory to, first-line chemoimmunotherapy. yescarta is indicated for the treatment of adult patients with relapsed or refractory (r/r) dlbcl and primary mediastinal large b cell lymphoma (pmbcl), after two or more lines of systemic therapy. yescarta is indicated for the treatment of adult patients with r/r follicular lymphoma (fl) after three or more lines of systemic therapy.